Last reviewed 2026-05-31 · How we verify

Eledone Peptide (ELEDOISIN)

Phase 2 active Recombinant protein ✓ Verified May 2026

Eledone Peptide (generic name: ELEDOISIN) is a drug. It is currently in Phase 2 development for Sjögren's syndrome.

Eledoisin works by binding to the Neuromedin-K receptor, which is involved in various physiological processes.

Eledone peptide, also known as Eledoisin, is a protein-based compound. It has several synonyms, including ELD 950, ELD-950, Eledoisin, Eledoisina, and Eledoisine.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ELEDOISIN
Target	Neuromedin-K receptor
Modality	Recombinant protein
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your body has a lock and key system. Eledoisin is a key that fits into a specific lock, called the Neuromedin-K receptor. When the key fits into the lock, it sends a signal to the body, which can help to reduce inflammation and other symptoms associated with Sjögren's syndrome.

Approved indications

Sjögren's syndrome

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eledone Peptide CI brief — competitive landscape report
Eledone Peptide updates RSS · CI watch RSS

Frequently asked questions about Eledone Peptide

What is Eledone Peptide?

Eledone Peptide (ELEDOISIN) is a Recombinant protein drug, indicated for Sjögren's syndrome.

How does Eledone Peptide work?

Eledoisin works by binding to the Neuromedin-K receptor, which is involved in various physiological processes.

What is Eledone Peptide used for?

Eledone Peptide is indicated for Sjögren's syndrome.

What is the generic name of Eledone Peptide?

ELEDOISIN is the generic (nonproprietary) name of Eledone Peptide.

What development phase is Eledone Peptide in?

Eledone Peptide is in Phase 2.

What does Eledone Peptide target?

Eledone Peptide targets Neuromedin-K receptor.

Target: All drugs targeting Neuromedin-K receptor
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Sjögren's syndrome

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing